Literature DB >> 30383135

Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care.

Xiaoxue Chen1, Abiy Agiro1, John Barron1, David Debono2, Michael Fisch3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30383135      PMCID： PMC6440708          DOI： 10.1001/jamaoncol.2018.5090

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Obstacles to the Adoption of Biosimilars for Chronic Diseases.

Authors:  Aaron Hakim; Joseph S Ross
Journal:  JAMA       Date:  2017-06-06       Impact factor: 56.272

2.  Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.

Authors:  Gary H Lyman
Journal:  J Oncol Pract       Date:  2017-09       Impact factor: 3.840

Review 3.  Biosimilars in Oncology in the United States: A Review.

Authors:  Chadi Nabhan; Sandeep Parsad; Anthony R Mato; Bruce A Feinberg
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

4.  Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

Authors:  Derek Weycker; Oleg Sofrygin; Kim Seefeld; Robert G Deeter; Jason Legg; John Edelsberg
Journal:  BMC Health Serv Res       Date:  2013-02-13       Impact factor: 2.655
  4 in total
  6 in total

Review 1.  Are Biosimilars the Future of Oncology and Haematology?

Authors:  Pier Luigi Zinzani; Martin Dreyling; William Gradishar; Marc Andre; Francisco J Esteva; Suliman Boulos; Eva González Barca; Giuseppe Curigliano
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

2.  Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Authors:  Kaniz Afroz Tanni; Cong Bang Truong; Sura Almahasis; Jingjing Qian
Journal:  BioDrugs       Date:  2021-01-13       Impact factor: 5.807

3.  Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.

Authors:  Ali Raza Khaki; Yong Shan; Richard E Nelson; Sapna Kaul; John L Gore; Petros Grivas; Stephen B Williams
Journal:  Urol Oncol       Date:  2021-03-23       Impact factor: 2.954

4.  Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.

Authors:  Prasad L Gawade; Shuling Li; David Henry; Nancy Smith; Rajesh Belani; Michael A Kelsh; Brian D Bradbury
Journal:  Support Care Cancer       Date:  2020-01-10       Impact factor: 3.603

5.  Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.

Authors:  Aaron B Mendelsohn; James Marshall; Cara L McDermott; Pamala A Pawloski; Jeffrey S Brown; Catherine M Lockhart
Journal:  Drugs Real World Outcomes       Date:  2021-01-30

Review 6.  Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa.

Authors:  Radwa Ahmed Batran; Mai Elmoshneb; Ahmed Salah Hussein; Omar M Hussien; Fady Adel; Reham Elgarhy; Mosaad I Morsi
Journal:  Biologics       Date:  2022-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.